 |
 |
 |
| |
 |
 |
| |
EnteroMedics Announces Updated Data From VBLOC DM2 ENABLE Study and Caloric Intake Study Results to Be Presented at the 29th Annual Obesity Society Meeting
October 3, 2011
EnteroMedics Announces Presentation of Maestro(R) RC System Clinical Data at the XVI World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders
September 2, 2011
Inviragen and University of Texas Medical Branch Receive Funding for Development of a
Novel Recombinant Chikungunya Virus Vaccine
August 15, 2011
San Diego's KFx Medical Corporation Files Patent Infringement Suit Against Arthrex
August 2, 2011
International Vaccine Institute and Inviragen Announce a Collaboration to Accelerate Development of a Dengue Vaccine
August 2, 2011
Minimally Invasive Devices, Inc. Awarded CE Mark for FloShield
July 20, 2011
Inviragen Initiates Phase 1 Study of Hand, Foot and Mouth Disease Vaccine in Singapore
June 15, 2011
EnteroMedics Announces Maestro® RC System Updated Weight Loss Data to Be Presented at the American Society for Metabolic and Bariatric Surgery Annual Meeting
June 14, 2011
EnteroMedics Announces First Implant in ReCharge Pivotal Trial for Obesity
May 18, 2011
Xlumena, Inc. Closes $7M Series B Venture Financing Round
April 28, 2011
EnteroMedics Receives CE Mark Certification for the Maestro RC System, Allowing Australian Regulatory Application to Move Forward
March 28, 2011
Inviragen and Duke-NUS Form Collaborative Vaccine Research and Development Program
January 26, 2011
EnteroMedics Announces Data From Australian Patient Cohort in EMPOWER Study and From Caloric Intake Study
November 8, 2010
Novel Recombinant Chikungunya Virus Vaccine Shown to be Safe and Effective in Multiple Animal Models
November 4, 2010
Inviragen Receives Two Therapeutic Discovery Project Grants for Vaccine Development
November 2, 2010
Inviragen Initiates DENVax Phase 1 Clinical Testing in Colombia
October 25, 2010
EnteroMedics Announces Updated Data from VBLOC-DM2, EMPOWER and VBLOC RF2 Studies
October 20, 2010
Inviragen and PharmaJet Receive $15.5 Million NIAID Contract to Develop a Needle-free Dengue Vaccine
October 12, 2010
EnteroMedics Completes $6.3 Million Convertible Preferred Stock Offering
September 30, 2010
EnteroMedics Achieves Major Milestones in Global Regulatory and Commercialization Strategy for the Maestro System
August 2, 2010
KFx Medical Corporation Announced Today It Has Received FDA 510k Clearance for Product(s) Used in a Wide Variety of Arthroscopic Tenodesis Knee Procedures Such as: ACL, PCL, and Patellofemoral Ligament (MPFL) Reconstruction
May 25, 2010
Inviragen’s Dengue Vaccine to Begin Clinical Testing
May 19, 2010
Inviragen Merger Profiled in Inc. Magazine
May 7, 2010
FDA Clears
Xlumena’s NAVIX™ Access
Device
April 28, 2010
EnteroMedics
Extends Neuroblocking Technology Research and Development
Collaboration
March
17, 2010
EnteroMedics Announces Regulatory Path
Forward Following FDA Meeting
March 15, 2010
EnteroMedics Announces Regulatory Path
Forward Following FDA Meeting
January
28, 2010
EnteroMedics Announces Weight Loss,
Hypertension and Diabetes Data from EMPOWER and ENABLE Studies
Januray
14, 2010
EnteroMedics Announces
Preliminary Results from Detailed Review of EMPOWER Study
November 12, 2009
Inviragen Merges with
SingVax and
Completes $15 million Series A Financing
October 6, 2009
KFx Medical Awarded Key Patent for Knotless Tissue Fixation and Double Row Rotator Cuff Surgery
September 9, 2009
Visioneering Technologies Raises $2.5M Series B
April 28, 2009
Visioneering Technologies Inc Raises $5 Million in Funding For New Presbyopia Solution
April 14, 2009
EnteroMedics Announces $15.89 Million Private Placement
February 20, 2009
EnteroMedics
Announces Eighteen-Month Excess Weight Loss Results from
its VBLOC-RF2 Feasibility Study
January 12, 2009
EnteroMedics
Announces $20 Million Debt Financing
November 21, 2008
APT Pharmaceuticals
Secures $32 Million in Series B Financing
September 30, 2008
EnteroMedics' Data from VBLOC-RF2 Feasibility Study and VBLOC-RC Study Presented Today at the American Society for Metabolic and Bariatric Surgery Meeting
June19, 2008
XLumena Spots $6M For Ultrasound Devices
June 4, 2008
Mirabilis Completes First Human Trial of Non-Invasive Treatment for Uterine Fibroids
APRIL 28, 2008
Astellas
and CoMentis Sign Agreement to Collaborate on the Research,
Development and Commercialization of Beta-Secretase Inhibitors
APRIL 25, 2008
EnteroMedics Announces Planned Expansion of EMPOWER Pivotal Study for Obesity to 300 Patients
February 26, 2008
KFx Medical Corporation Appoints Matt Meyer
as its Vice President Marketing
February 20, 2008
EnteroMedics(TM) Announces Nine-Month Clinical Results on Its VBLOC-RF2 Feasibility Study for Obesity Therapy
January 8, 2008
EnteroMedics(TM) Announces Pivotal Clinical Study of its VBLOC(TM) Therapy for Obesity
January 7, 2008
CoMentis Announces Proof-of-Activity-Data from its Phase I Study of Disease-Modifying Alzheimer’s Disease Therapy
January 7, 2008
APT
Pharmaceuticals Expands Management Team
NOVEMBER 19, 2007
EnteroMedics
Announces Initial Public Offering
NOVEMBER 14, 2007
APT
Pharmaceuticals Closes New $22 Million Funding Round
OCTOBER 4, 2007
JDRF Partners with CoMentis for Diabetic Macular Edema Clinical Trial
SEPTEMBER 20, 2007
Mirabilis
Closes $10.5 Million Series A Extension to Commercialize
Non-invasive Treatment of Uterine Fibroids
AUGUST 21, 2007
KFx Medical
Corporation Closes $10 Million Series B Financing
AUGUST 9, 2007
JDRF Partners with CoMentis for Diabetic Macular Edema Clinical Trial
JUNE 18, 2007
CoMentis Announces Appointment of Martin Tolar, M.D., Ph.D., as Vice President
JUNE 6, 2007
APT Acquires
Exclusive Worldwide Rights to Develop and Commercialize
Inhalable Cyclosporine to Prevent Lung Transplant Rejection
JUNE 5, 2007
Enteromedics
Files Registration Statement
for Proposed Initial Public Offering
MAY 25, 2007
CoMentis Initiates Phase II Clinical Trial for AMD Eye Drop Therapy
APRIL 10, 2007
Athenagen
Announces Name Change to CoMentis
FEBRUARY 10, 2007
Athenagen’s
Eye Drop Therapy for AMD is Safe and Well Tolerated in
Phase I Study
JANUARY 31, 2007
Athenagen
Initiates Phase II Clinical Trial in Alzheimer’s
Disease
DECEMBER 13, 2006
Mirabilis
Medica Names Mike Connolly CEO
OCTOBER 3, 2006
Athenagen
Raises $50 Million in Series B Financing
SEPTEMBER 28, 2006
Amaranth
Medical Closes $7.5 Million Series A Financing to Advance
the Development of Bio-Absorbable Stents
SEPTEMBER 26, 2006
Mirabilis
Raises $4 Million to Commercialize Non-Invasive Treatment
of Uterine Fibroids
AUGUST 29, 2006
Athenagen
Initiates Clinical Development of its Anti-angiogenic Eye
Drop Therapy for AMD
AUGUST 21, 2006
Athenagen
Completes Merger with Zapaq
AUGUST 14, 2006
KFx Medical
Corporation Receives 510k Clearance for Knotless Tissue
Fixation
AUGUST 10, 2006
Athenagen
Announces Publication of Results from a Proof-of-Concept
Trial of its Novel alpha-7 Nicontinic Receptor Agonist
in Schizophrenia
JUNE 15, 2006
Athenagen
Acquires Osprey Pharmaceutical Company - Adds Clinical-Stage
Alzheimer's Drug Candidate to its Pipeline
APRIL 13, 2006
Aradigm
and APT Pharmaceuticals Initiate Phase 2 Clinical Program
of Novel Treatment for Asthma
MARCH 23, 2006
Athenagen
Adds A. Barr Dolan to its Board of Directors
FEBRUARY 22, 2006
Previous
News Stories > |
|
| |
|
|
|
 |
 |
 |
| |
Athenagen Acquires Osprey
Pharmaceutical Company- Adds Clinical-Stage Alzheimer's Drug
Candidate to its Pipeline
SOUTH SAN FRANCISCO, CA and PONTE VEDRA BEACH,
FL – APRIL 13, 2006
Athenagen, Inc., a privately held biopharmaceutical
company, announced today that it has acquired the assets of
Osprey Pharmaceutical Company, which include a lead clinical
compound targeting Alzheimer's disease, as well as a large
library of related analogs. The lead compound, GTS-21, is a
novel, orally active alpha-7 nicotinic acetylcholine (nACh)
receptor agonist that has demonstrated memory and cognition
enhancement activity in Phase I studies. The acquisition also
includes intellectual property, preclinical and clinical data,
and an active U.S. IND for GTS-21. Financial terms were not
disclosed.
Osprey's lead compound, GTS-21 (also known
as DMXBA), is unique in that it is a selective alpha-7 nicotinic
acetylcholine receptor agonist. GTS-21 has been studied in
four Phase I studies in healthy volunteers and one Phase I
study in schizophrenic patients. In all studies, the compound
was well tolerated. In a Phase I multi-dosing, double-blind,
placebo controlled study in healthy adults, cognitive enhancement
was seen across all doses, with a statistically significant
improvement in attention related and memory related tasks (Kitagawa
et al., Neuropsychopharmacology (2003) 28, 542-551). Athenagen
plans to initiate Phase II studies in patients with Alzheimer's
disease in early 2007.
"GTS-21 is an excellent addition to
our pipeline because it expands our nACh receptor- focused
clinical portfolio with an additional therapeutic indication
- Alzheimer's disease," stated W. Scott Harkonen, M.D.,
President and Chief Executive Officer. "Osprey's drug
discovery efforts in cognition and memory with the alpha-7
nACh receptor pathway in the brain complement Athenagen's scientific
work on the endothelial nACh receptor pathway for diseases
associated with angiogenesis. With our age-related macular
degeneration (AMD) program and wound healing programs advancing
to the clinic this year, and our first Alzheimer's Phase II
trials planned to start early next year, Athenagen expects
to have three Phase II programs underway in 2007."
The portfolio of compounds acquired by Athenagen
was originally licensed by Osprey from the University of Florida
in Gainesville. Osprey's technology is based on pioneering
work conducted by William R. Kem, Ph.D., Professor in the Department
of Pharmacology and Therapeutics. Dr. Kem is an expert in identifying
compounds that bind to alpha-7 nACh receptors and was one of
the first to characterize the role of alpha-7 nACh receptors
in cognition and memory. The alpha-7 nACh receptor has been
shown to stimulate cognition without causing addiction or other
side effects associated with stimulation of other nACh receptors.
Athenagen will continue to work with Dr. Kem in developing
novel nACh receptor agonists and characterizing their uses.
"The portfolio of compounds developed
by Dr. Kem offer a number of additional opportunities for Athenagen," stated
John Cooke, M.D., Ph.D, co-founder of Athenagen and Chief Scientific
Officer. "We are enthusiastic about the opportunity to
combine his expertise in the nACh field with ours."
"Our drug discovery research group
is extremely pleased that Athenagen will be continuing to support
our ongoing efforts," commented Dr. Kem. "In addition
to Alzheimer's disease, there are several interesting therapeutic
applications that are being explored which further enhance
the drug discovery and development programs at Athenagen." |
|
| |
|
|
| |
|
|
| |
About Osprey
Pharmaceutical
Osprey Pharmaceutical Company, Ponte
Vedra Beach, Florida, was founded in 2003 by Stefan
Borg, a biotechnology veteran and entrepreneur, who
served as the company's President and CEO until his
sudden death in May 2005. The company planned to commercialize
the lead compound in Dr. Kem's portfolio and expand
on opportunities afforded by numerous other compounds
in the portfolio that it licensed from the University
of Florida in Gainesville. Mr. Borg had previously
started two biotechnology life science companies including
SunPharm Corporation (a public corporation now part
of Genzyme). Mr. Borg was succeeded by Paul Herron,
Osprey's Chief Financial Officer, as the interim President
and CEO. Mr. Herron had worked previously with Mr.
Borg as CFO of two other biotechnology companies, including
SunPharm.
About Athenagen
Athenagen, Inc., located in South San Francisco,
is engaged in the development of small-molecule drugs designed
to either inhibit or enhance angiogenesis, based on the discovery
of a new endothelial cell angiogenesis pathway, known as
the nicotinic acetylcholine (nACh) receptor pathway. Athenagen's
lead products are being developed as oral and topical compounds
to treat diseases caused by enhanced angiogenesis, such as
cancer and age-related macular degeneration (AMD), as well
as topical formulations to treat diseases caused by impaired
angiogenesis, such as non-healing wounds. Athenagen plans
to introduce two drug candidates into the clinic in 2006:
ATG002, a topical pro-angiogenesis compound for diabetic
foot ulcers and ATG003, a topical (eye drop) anti-angiogenesis
compound for neovascular AMD. In addition, Athenagen expects
to enter Phase II clinical trials with a third program, GTS-21,
for Alzheimer's disease in early 2007.
For more information: www.athenagen.com.
CONTACT:
W. Scott Harkonen, M.D.
President and CEO
(650) 869-7600
press@athenagen.com |
|
| |
|
|
|